Compare DexCom, Inc. (DXCM) vs Vistra Corp (VST) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
DexCom, Inc. vs Vistra Corp — how do they compare? DexCom, Inc. trades at $84.38 (market cap $31.86B), while Vistra Corp trades at $158.3 (market cap $52.41B). The key difference: Vistra Corp is the larger of the two by market cap, and Vistra Corp pays a 0.59% dividend while DexCom, Inc. pays none. Which is the better fit depends on your goals — on Pluang, investors hold DexCom, Inc. for 62 Days and Vistra Corp for 32 Days on average.
| DXCM | VST | |
|---|---|---|
Market Cap | $31.86B | $52.41B |
Volume | 3,607,070 | 11,278,074 |
Sector | Health | Utilities |
52-Week High | $92.34 | $210.85 |
52-Week Low | $54.84 | $134.71 |
Typical Hold Time | 62 Days | 32 Days |
Enterprise Value | $31.32B | $74.34B |
Dividend Yield | — | 0.59% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
DXCM trades at $84.3, up 1.09% today, with a bearish technical signal but strong fundamentals. Revenue grew to $4.66B in 2025, with net income of $836.3M and a 17.93% margin. The stock has a P/E of 33.32 and P/S of 6.74. Recent news highlights growth in CGM adoption for Type 2 diabetes. Analyst consensus is bullish with an average price target of $95.07, supported by 42 buy ratings.
Outlook remains positive due to earnings beats and market expansion, but risks include competition and reimbursement challenges. The stock offers growth potential, yet investors should monitor execution against high valuations and technical resistance near $85.
Vistra Corp (VST) trades at $166.72, up 3.88% with strong analyst support (91% buy ratings) and a $215.23 consensus target. The stock shows bullish technical momentum above key support at $162, while fundamentals reveal impressive 75.73% ROE and 11.55% net margin. Recent developments include a $4.2 billion US loan for nuclear expansion and a 20-year power deal with New Era Energy, positioning VST to capitalize on AI-driven electricity demand.
Vistra offers compelling exposure to the AI power infrastructure theme with strong profitability and government backing, though investors face earnings volatility risks as seen in recent quarterly misses. The stock trades at a premium valuation (P/E 26.33) but maintains upside potential if execution on nuclear expansion and data center contracts meets expectations.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About DexCom, Inc.
Dexcom designs and commercializes continuous glucose monitoring systems for diabetics. CGM systems serve as an alternative to the traditional blood glucose meter process, and the company is evolving its CGM systems to include the disposable sensor and the durable receiver.
Read more on DXCM →About Vistra Corp
Vistra is a leading integrated retail electricity and power generation company that serves as a critical infrastructure provider for the digital economy. It operates a diversified portfolio of zero-carbon nuclear and renewable assets alongside a massive, flexible natural gas fleet, positioning it as an indispensable partner for energy-intensive AI data centers and industrial electrification.
Read more on VST →
